|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo Finance health care reporter Anjalee Khemlani shares the latest on the ongoing baby formula shortage and how it may extend into spring 2023.
Drug company Perrigo (NYSE: PRGO) experienced quite a headache on Tuesday after it released its third-quarter report before the bell. For the period, Perrigo booked total sales of $1.1 billion, which was nearly 6% higher on a year-over-year basis. Perrigo has a wide range of products in its portfolio.